Market
Which condition will semaglutide most significantly impact in reducing cardiovascular events by end of 2025?
2
Resolution / Starting Odds
Heart Disease • 25%
Stroke • 25%
Chronic Kidney Disease • 25%
Other • 25%
Peer-reviewed medical journals and clinical trial results
Story
Semaglutide Reduces Heart Disease, Stroke, and Treats Kidney Disease, Alzheimer's
Dec 14, 2024, 05:00 PM
New research indicates that semaglutide, the active ingredient in popular weight-loss drugs like Ozempic and Wegovy, may have benefits extending beyond weight management. Studies suggest that semaglutide can reduce the risk of heart attack, stroke, and even curb addiction. The drug has shown a 20% reduction in cardiovascular events and all-cause mortality in clinical trials. Moreover, semaglutide has been linked to improvements in conditions like diabetic macular edema, obstructive sleep apnea, metabolic liver dysfunction, and Alzheimer's disease. The European Medicines Agency has recently approved Ozempic for the treatment of chronic kidney disease, highlighting a 24% reduction in disease progression risk. However, while the drug's potential is vast, experts caution that not all patients will respond to the treatment, and further research is needed to understand its full range of effects and safety.
View original story
Similar markets
Dementia • 25%
Heart attack • 25%
Schizophrenia • 25%
Substance abuse • 25%
Weight loss > 20.7% • 25%
Weight loss between 17.5% and 19% • 25%
Weight loss < 17.5% • 25%
Weight loss between 19% and 20.7% • 25%
Kidney stones • 25%
Gastrointestinal issues • 25%
Pancreatitis • 25%
Other condition • 25%
20% to 22% weight loss • 25%
22% to 24% weight loss • 25%
More than 24% weight loss • 25%
Less than 20% weight loss • 25%
Less than 25% reduction • 25%
70% or more reduction • 25%
50-69% reduction • 25%
25-49% reduction • 25%
Type 2 Diabetes • 25%
Other • 25%
Alzheimer's Disease • 25%
Obesity • 25%
Mixed findings • 25%
More benefits • 25%
More risks • 25%
No significant new findings • 25%
No • 50%
Yes • 50%
Study retracted • 25%
Inconclusive results • 25%
No significant risk found • 25%
Confirms significant risk • 25%